HER2 Quiz

Quiz

Novel Antibody-Drug Conjugate MRG002 Payload

09/25/2025

Do you know the payload for the novel antibody-drug conjugate MRG002? Take our quick quiz to find out!

Do you know the payload for the...

09/25/2025

Oncology

Quiz

Rethinking the Role of Carboplatin in Early HER2-Positive Breast Cancer Neoadjuvant Therapy

08/25/2025

The phase 3 neoCARHP study evaluated the efficacy and safety of a de-escalated neoadjuvant regiment of taxane plus trastuzumab and pertuzumab, without carboplatin, among patients with HER2-positive early breast cancer. What was the broader...

The phase 3 neoCARHP study...

08/25/2025

Oncology

Quiz

Pertuzumab Retreatment for Patients With HER2-Positive Breast Cancer

04/11/2025

Did the addition of pertuzumab retreatment to trastuzumab and physician’s choice chemotherapy improve survival among patients with HER2-positive, locally advanced or metastatic breast cancer?

Did the addition of pertuzumab...

04/11/2025

Oncology

Quiz

Trastuzumab Emtansine for HER2-Positive Early Breast Cancer

02/07/2025

Did trastuzumab emtansine improve invasive disease-free survival compared to trastuzumab in patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy?

Did trastuzumab emtansine...

02/07/2025

Oncology

Quiz

SHR-A1811 for HER2-Expressing Advanced Solid Tumors

10/03/2024

Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!

Do you know whether SHR-A1811...

10/03/2024

Oncology

Quiz

Quiz: Does Trastuzumab Deruxtecan Show Greater Efficacy than Standard of Care in HER2-Positive BC?

04/26/2022

True or false: Trastuzumab deruxtecan was associated with significantly lower risk of disease progression over current standard of care for HER2-positive metastatic breast cancer.

True or false: Trastuzumab...

04/26/2022

Oncology

Test Your Knowledge

Quiz: Is Trastuzumab Deruxtecan Superior to Chemo in HER2+ Gastric Cancer?

02/04/2022

True or false: Trastuzumab deruxtecan showed superiority over chemo in HER2+ gastric cancer.

True or false: Trastuzumab...

02/04/2022

Oncology

Test Your Knowledge

Quiz: What HER2 Targeted Therapies are Approved for NSCLC?

01/31/2022

True or false: Currently, there are many HER2 targeted therapies approved for NSCLC.

True or false: Currently, there...

01/31/2022

Oncology

Quiz

Quiz: Does Adjuvant Olaparib or Placebo Provide Longer OS in HER2-Negative Breast Cancer?

08/20/2021

True or false: In a recent phase 3 study for patients with HER2-negative early breast cancer with BRCA1 or BRCA2 germline mutations, placebo induction showed superior survival benefit in comparison to adjuvant olaparib.

True or false: In a recent phase...

08/20/2021

Oncology

Recent News

News

Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL

09/26/2025

Emily Estrada

The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.

The implementation of R-ICE...

09/26/2025

Oncology

News

PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL

09/26/2025

Emily Estrada

Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.

Treatment of R/R diffuse large...

09/26/2025

Oncology

News

Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies

09/26/2025

Emily Estrada

Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Compared with traditional...

09/26/2025

Oncology

FDA Approval

FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

09/25/2025

Stephanie Holland

The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.

The FDA has approved...

09/25/2025

Oncology

News

Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors

09/25/2025

Allison Casey

Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.

Pexidartinib showed sustained...

09/25/2025

Oncology

News

Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma

09/24/2025

Emily Estrada

For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.

For patients with...

09/24/2025

Oncology

News

First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer

09/23/2025

Stephanie Holland

Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...

Results from the phase 2/3...

09/23/2025

Oncology

News

Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.

According to a phase 2a trial,...

09/23/2025

Oncology

News

Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.

According to an analysis of the...

09/23/2025

Oncology

News

Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer

09/22/2025

Stephanie Holland

According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...

According to results from the...

09/22/2025

Oncology